Looking ahead to 2025, Sandoz said it expects net sales to grow by a mid-single digit percentage in constant currencies.

This marks the second biosimilar ... looking statements generally relate to future events or the future financial operating performance of Alvotech and may include, for example, Alvotech’s ...

In October 2024, the FDA approved the biosimilar ... statements generally relate to future events or the future financial operating performance of Alvotech and may include, for example, Alvotech ...

"We are extremely pleased with this new step in the development of our biosimilar ... Forward-looking statements generally relate to future events or the future financial operating performance of ...

Record Year with Total 2024 Revenues of $161.0 Million, Representing a 13% Increase over Fiscal Year 2023 and Adjusted EBITDA ...

Barclays 27th Annual Global Healthcare Conference Call March 12, 2025 2:00 PM ETCompany ParticipantsBrian Evanko - Chief ...

Dr. Marty Makary, President Donald Trump’s pick to lead the FDA, sidestepped some questions through his confirmation hearing ...

Dr. Marty Makary, Trump's nominee for FDA Commissioner, breezed through his confirmation hearing despite tough questions from Democrats and Republicans.

Mía had dystrophic epidermolysis bullosa, better known as butterfly skin due to the extreme fragility of this tissue in ...

The Swiss pharma group said this morning that the separation "is in the best interest of shareholders" and will create the number one generics company in Europe and a leader in biosimilars ...